Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Recruiting 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 13144Triple Negative Breast Neoplasms 1151Neoplasms 751Ovarian Neoplasms 680Neoplasm Metastasis 591Lung Neoplasms 583Colorectal Neoplasms 581Prostatic Neoplasms 560Carcinoma, Non-Small-Cell Lung 536Pancreatic Neoplasms 380Melanoma 366Stomach Neoplasms 350Colonic Neoplasms 330Motor Activity 285Breast Neoplasms, Male 285Carcinoma, Intraductal, Noninfiltrating 277Uterine Cervical Neoplasms 267Head and Neck Neoplasms 266Endometrial Neoplasms 256Carcinoma, Renal Cell 216Sarcoma 204Urinary Bladder Neoplasms 193Squamous Cell Carcinoma of Head and Neck 192Lymphedema 190Esophageal Neoplasms 189Breast Carcinoma In Situ 189Brain Neoplasms 183Fatigue 166Carcinoma, Ovarian Epithelial 151Small Cell Lung Carcinoma 148

Interventions

Letrozole 2ribociclib 1palbociclib 1abemaciclib 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Fulvestrant 1Epirubicin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
HR+/HER2- Breast Cancer × Breast × Clear all
NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting
1,056 enrolled
Breast

HR+/HER2- Breast Cancer

NCT06998407 2026-05-04

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting
380 enrolled
Breast

HR+/HER2- Breast Cancer

NCT07130643 2025-08-19

Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer

Hubei Cancer Hospital

Phase 2 Active not recruiting
40 enrolled
Breast

HR+/HER2- Breast Cancer

NCT06860529 2025-06-23

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Henan Cancer Hospital

Phase 2 Recruiting
357 enrolled
Breast

HR+/HER2- Breast Cancer

NCT05633914 2023-02-21

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Hunan Cancer Hospital

Phase 2 Unknown
90 enrolled
Breast

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡